|
Change from baseline in DAS28-CRP score (95% CI)
|
Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA
|
− 0.107 (− 0.309; 0.095), p = 0.3012
|
− 0.587 (− 0.834; − 0.34), p < 0.0001
|
− 0.693 (− 0.993; − 0.393), p < 0.0001
|
− 0.578 (− 0.831; − 0.325), p < 0.0001
|
|
Change from baseline in CDAI score (95% CI)
|
Race, baseline CDAI, anti-CPP, HAQ-DI, PADA
|
− 1.138 (− 2.912; 0.636), p = 0.2087
|
− 3.551 (− 5.742; − 1.36), p = 0.0016
|
− 4.690 (− 7.438; − 1.942), p = 0.0009
|
− 3.502 (− 5.715; − 1.289), p = 0.002
|
|
Change from baseline in SDAI score (95% CI)
|
Race, baseline SDAI, anti-CPP, HAQ-DI, PADA
|
− 1.109 (− 2.983; 0.765), p = 0.2462
|
− 4.079 (− 6.411; − 1.747), p = 0.0006
|
− 5.188 (− 8.104; − 2.272), p = 0.0005
|
− 4.031 (− 6.385; − 1.677), p = 0.0008
|
|
Proportion of patients achieving a EULAR good response (CRP criteria)
|
Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA
|
1.293 (0.913; 1.831), p = 0.1482
|
2.066 (1.389; 3.071), p = 0.0004
|
2.671 (1.722; 4.142), p < 0.0001
|
2.268 (1.556; 3.305), p < 0.0001
|
|
Proportion of patients achieving ACR20 response
|
Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental
|
1.129 (0.806; 1.584), p = 0.4803
|
1.442 (0.765; 2.716), p = 0.2580
|
1.628 (0.797; 3.329), p = 0.1818
|
1.439 (0.763; 2.712), p = 0.261
|
|
Proportion of patients achieving ACR50 response
|
Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental
|
1.133 (0.802; 1.601), p = 0.4777
|
1.601 (1.019; 2.514), p = 0.0414
|
1.814 (1.033; 3.185), p = 0.0384
|
1.597 (1.016; 2.51), p = 0.0429
|
|
Proportion of patients achieving ACR70 response
|
Baseline PADA, anti-CPP, CRP, HAQ-DI, SF-36 Mental
|
1.256 (0.804; 1.965), p = 0.3171
|
1.731 (1.087; 2.758), p = 0.0211
|
2.176 (1.154; 4.102), p = 0.0165
|
1.72 (1.078; 2.746), p = 0.0231
|
|
Proportion of patients achieving DAS-28-CRP low disease activity: DAS28-CRP ≤ 3.2
|
Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA
|
1.248 (0.88; 1.771), p = 0.2137
|
2.097 (1.406; 3.127), p = 0.0003
|
2.618 (1.684; 4.07), p < 0.0001
|
2.273 (1.556; 3.322), p < 0.0001
|
|
Proportions of patients with DAS28-CRP remission: DAS28-CRP < 2.6
|
Race, baseline DAS28-CRP, anti-CPP, BMI, HAQ-DI, PADA
|
1.218 (0.822; 1.806), p = 0.3258
|
2.308 (1.509; 3.531), p = 0.0001
|
2.812 (1.747; 4.528), p < 0.0001
|
2.481 (1.660; 3.707), p < 0.0001
|
|
Proportion of patients achieving CDAI low disease activity: CDAI ≤ 10.0
|
Race, CDAI initial, anti-CPP, HAQ-DI, PADA
|
1.447 (1.029; 2.035), p = 0.0341
|
2.11 (1.427; 3.120), p = 0.0002
|
3.053 (1.980; 4.708), p < 0.0001
|
2.030 (1.312; 3.142), p = 0.0015
|
|
Proportions of patients achieving CDAI remission: CDAI ≤ 2.8
|
Race, CDAI initial, anti-CPP, HAQ-DI, PADA
|
1.291 (0.699; 2.384), p = 0.4145
|
1.224 (0.662; 2.263), p = 0.52
|
1.58 (0.679; 3.678), p = 0.2891
|
1.213 (0.654; 2.25), p = 0.5412
|
|
Proportion of patients achieving SDAI low disease activity: SDAI ≤ 11.0
|
Race, SDAI initial, anti-CPP, HAQ-DI, PADA
|
1.384 (0.985; 1.944), p = 0.0616
|
2.066 (1.392; 3.066), p = 0.0003
|
2.859 (1.850; 4.418), p < 0.0001
|
2.111 (1.383; 3.223), p = 0.0006
|
|
Proportions of patients achieving SDAI remission: SDAI ≤ 3.3
|
Race, SDAI initial, anti-CPP, HAQ-DI, PADA
|
1.337 (0.729; 2.454), p = 0.3487
|
1.23 (0.677; 2.233), p = 0.4967
|
1.644 (0.716; 3.779), p = 0.2417
|
1.219 (0.669; 2.219), p = 0.5179
|
|
Proportions of patients with Boolean remission
|
PADA, CRP, age, BMI
|
1.824 (0.54; 6.165), p = 0.3337
|
2.552 (0.926; 7.034), p = 0.0704
|
4.655 (1.105; 19.622), p = 0.0364
|
2.422 (0.846; 6.938), p = 0.0997
|
|
Proportion of patients achieving HAQ MCID improvement
|
HAQ-DI, age, SF-36 mental
|
1.505 (1.026; 2.208), p = 0.0370
|
1.549 (0.933; 2.57), p = 0.0908
|
2.331 (1.307; 4.158), p = 0.0043
|
1.67 (1.065; 2.619), p = 0.0258
|
